FIGURE 1.
Treatment pathway of a patient with PTC who progressed on sorafenib and lenvatinib, and who achieved a complete response with larotrectinib treatment. AE, adverse event; PTC, papillary thyroid cancer; RAI, radioactive iodine
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.